(Reuters) - Medivation Inc's experimental prostate cancer pill caused fewer serious side effects in clinical trial patients than a placebo treatment, according to full results from a pivotal study announced on Tuesday. The news sent shares of Medivation up more than 11 percent to $61.75 in after-hours trading. Medivation and partner Astellas Pharma Inc reported in November that the trial had ...